Depression is a common illness that causes feelings of sadness, hopelessness, or despair. When depression is severe and lasts longer than 2 weeks, it is referred to as major or clinical depression. While everyone feels sad or low from time to time, a person suffering from major depression experiences symptoms that linger for weeks and months and interferes with their daily routine. It's estimated that between 20-25 percent of adults may suffer an episode of major depression at some point in their lifetime. Many cases of depression can be traced to specific life events and are successfully treated through a combination of medication and counseling.

Depression is typically characterized by left hemisphere hypoactivity in addition to right hemisphere hyper-activation. tDCS increases spontaneous brain activity and metabolism in areas found to be hypoactive in depressed patients. Further, tDCS when combined with antidepressant sertraline in a study has shown increase in efficacy of each treatment conducted separately. The efficacy and safety of tDCS and sertraline was shown to not differ in this study.

Depression tDCS-LTE™ system offers a new path for patients by providing safe and effective brain stimulation with a device that does not require anesthesia and does not cause memory loss, does not need surgery, and has no seizure risk.

tDCS-LTE is an exclusive neuromodulation technology developed by Soterix Medical Inc. tDCS-LTE is the only tDCS technology platform optimized for robust low-energy Transcranial Direct Current Stimulation. tDCS-LTE is made possible through a proprietary adaptive stimulation limiting the voltage and power required for tDCS while enhancing current delivery to the brain regions responsible for mood elevation.